Talk:Factor VIII
From Wikipedia, the free encyclopedia
 |
This article is part of WikiProject Genetics, an attempt to build a comprehensive and detailed guide to genetics on Wikipedia. If you would like to participate, you can edit this page, or visit the project page to join the project and/or contribute to the discussion. |
| ??? | This article has not yet received a rating on the quality scale. |
| ??? | This article has not yet received an importance rating. |
 |
This article is supported by the WikiProject on Medical Genetics, which gives a central approach to Medical genetics and related subjects on Wikipedia. Please participate by editing the article Factor VIII, or visit the project page for more details on the projects. |
| Start | This article has been rated as Start-Class on the quality scale. |
 |
This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme. |
||
| Start | This article has been rated as start-Class on the assessment scale. |
||
| Mid | This article is on a subject of mid-importance within molecular and cellular biology. | ||
|
Article Grading: The article has been rated for quality and/or importance but has no comments yet. If appropriate, please review the article and then leave comments here to identify the strengths and weaknesses of the article and what work it will need. |
|||
 |
This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Mid | This article has been rated as Mid-importance on the importance assessment scale |
[edit] Controversy
I really think that this section needs more evidence than a few minutes of footage from an op-ed TV programme. The YouTube clip mentions several investigations conducted by various organisations, including the New York Times; were are these references? I'll have a look around, and see what I can find. MachiavellianMeow 15:49, 20 June 2007 (UTC)
I agree that this is a pretty inflamatory statement that needs more backup. —Preceding unsigned comment added by 68.205.188.74 (talk) 18:17, 7 September 2007 (UTC)
Well, here's a NY times article on the issue:
http://query.nytimes.com/gst/fullpage.html?res=9A00E4DA1F3EF931A15756C0A9659C8B63 I'll add something to the article about this.--140.77.129.149 (talk) 19:55, 16 December 2007 (UTC)
From Baxter's SEC document: On May 6, 1997, the U.S.D.C. approved a class action settlement submitted by the plaintiffs' steering committee for the MDL, Baxter, Alpha Therapeutic Corporation, Armour Pharmaceutical and Bayer Corporation. The essential terms of the settlement provide payments of $100,000 to each HIV-positive person with hemophilia in the United States who can demonstrate use of factor concentrates produced by one of the settling defendants between 1978 and 1985. Additionally, the defendants have established a $40 million fund for payment of attorneys' fees, costs and court-administration expenses. Baxter's agreed contribution to the proposed settlement is 20 percent of the total settlement proceeds. Nukeh (talk) 00:43, 24 February 2008 (UTC)
It appears the Factor 8 harvested from blood was selling for $50 per vial (e.g., pediatric dose). Then the contamination problem was found (HIV, HCB), and the shift over to recombinatant, genetically engineered cells (CHO) was made. The price went to $300 per vial, and it appears that governments with universal health care and /or people without the appropriate insurance could no longer afford Factor 8. This is basically "inside information", and it will take some research to find a reference that does not constitute original research by combining multiple references in a time-course. I stumbled into this area in an attempt to get some Factor 8 to a dying child in Mexico, and I now have a lot of very hostile and defensive email coming in from old buddies in biotech. Nukeh (talk) 13:07, 26 February 2008 (UTC)
- Please post any references here for discussion. Is there anything known in terms of cost-benefit ratio? Surely if the procuct is safer it has less knock-on costs in terms of dealing with viral contamination and inhibitors. That would not have helped the Mexican patient in question (was there really no way of getting a compassionate discount?), but would put the pricing in perspective. JFW | T@lk 15:53, 26 February 2008 (UTC)
[edit] Cerus and Baxter
CERUS AND BAXTER REPORT PRIMARY ENDPOINT MET IN U.S. PHASE III TRIAL OF THE INTERCEPT PLASMA SYSTEM
Data Supports Submission for US Regulatory Approval
CONCORD, Calif., and DEERFIELD, Ill., August 17, 2001 - Cerus Corporation (Nasdaq: CERS) and Baxter Healthcare Corporation today reported that the INTERCEPT Plasma System successfully met the primary endpoint of their US Phase IIIb clinical trial. These data further support the safety and therapeutic effectiveness of plasma treated with the INTERCEPT Plasma System, which is being developed to protect against transmission of infectious diseases that may result from plasma transfusions. "These results are significant because they demonstrate that we can offer the pathogen inactivation process with the INTERCEPT Plasma System while maintaining therapeutic performance," said Stephen T. Isaacs, president and chief executive officer of Cerus. "These results will be added to our arsenal of data supporting the safety and efficacy of the INTERCEPT Plasma System, including preclinical studies demonstrating inactivation of a broad spectrum of blood borne pathogens." From: http://www.baxter.com/about_baxter/news_room/news_releases/2001/08-17plasma3.html Nukeh (talk) 01:06, 24 February 2008 (UTC)
[edit] Liposomes and PEG
doi:10.1111/j.1538-7836.2007.02856.x JFW | T@lk 07:00, 27 November 2007 (UTC)
